Trial Profile
A Phase II Trial of Sorafenib (a tyrosine kinase inhibitor) given orally twice daily in renal cancer patients with vHL syndrome.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 25 Jul 2011
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Renal cancer
- Focus Therapeutic Use
- 25 Jul 2011 New trial record